IL17RB and neoplasm: Every study point to the hindrance of the IL-17B/IL-17RB axis through downregulation of receptor expression in tumour cells, utilising diffusing anti-IL-17RB antibodies, reestablished in vitro and in vivo chemosensitivity [77].